SEC INSIDER TRANSACTIONS

QUEST DIAGNOSTICS INC (DGX) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

DGX · QUEST DIAGNOSTICS INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 39 filings · fetched 2026-11-13T17:19:48Z

Recent reported activity

0purchase rows on this page

6sale rows on this page

63matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-10-21Filed 2026-10-23	KUPPUSAMY KARTHIKOfficer · SVP, Clinical Solutions Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. References: F1, F2	L Other reported codeCommon Stock · Non-derivative	33A	235.944	Direct	Form 4 ↗0001022079-26-000113
2026-10-21Filed 2026-10-23	Gregg Vicky BDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	A Award / grantCommon Stock · Non-derivative	63A	235.939	Direct	Form 4 ↗0001022079-26-000114
2026-10-21Filed 2026-10-23	SAMAD SAMOfficer · Executive Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	A Award / grantCommon Stock · Non-derivative	90A	235.939	Direct	Form 4 ↗0001022079-26-000115
2026-10-21Filed 2026-10-23	CARTER ROBERT BDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	10A	235.93	Direct	Form 4 ↗0001022079-26-000116
2026-10-01Filed 2026-10-02	WENTWORTH TIMOTHY CDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. References: F1	A Award / grantPhantom Stock Units · Derivative	135A	0	Direct	Form 4 ↗0001022079-26-000090
2026-09-01Filed 2026-09-03	Davis J. E.Director · Officer · CEO and President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. References: F1	S Sale (market/private)Common Stock · Non-derivative	10,000D	242.72	Direct	Form 4 ↗0001599837-26-000007
2026-08-28Filed 2026-08-31	PREVOZNIK MICHAEL EOfficer · SVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. F6 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1, F7	M Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative	22,677D	112.17	Direct	Form 4 ↗0001022079-26-000089
2026-08-28Filed 2026-08-31	PREVOZNIK MICHAEL EOfficer · SVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. F6 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F5	G GiftCommon Stock · Non-derivative	1,000D	0	Direct	Form 4 ↗0001022079-26-000089
2026-08-28Filed 2026-08-31	PREVOZNIK MICHAEL EOfficer · SVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. F6 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	430D	244.5148	Direct	Form 4 ↗0001022079-26-000089
2026-08-28Filed 2026-08-31	PREVOZNIK MICHAEL EOfficer · SVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. F6 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	6,237D	243.6275	Direct	Form 4 ↗0001022079-26-000089
2026-08-28Filed 2026-08-31	PREVOZNIK MICHAEL EOfficer · SVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. F6 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	16,010D	242.8755	Direct	Form 4 ↗0001022079-26-000089
2026-08-28Filed 2026-08-31	PREVOZNIK MICHAEL EOfficer · SVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. F6 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F7 The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. References: F1	M Exercise / conversionCommon Stock · Non-derivative	22,677A	112.17	Direct	Form 4 ↗0001022079-26-000089
2026-07-28Filed 2026-07-29	DELANEY MARK EOfficer · SVP & Chief Commercial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. References: F1	S Sale (market/private)Common Stock · Non-derivative	1,600D	235.18	Direct	Form 4 ↗0001022079-26-000087
2026-07-22Filed 2026-07-27	KUPPUSAMY KARTHIKOfficer · SVP, Clinical Solutions Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. References: F1, F2	L Other reported codeCommon Stock · Non-derivative	37A	206.807	Direct	Form 4 ↗0001022079-26-000086
2026-07-22Filed 2026-07-27	CARTER ROBERT BDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	11A	206.804	Direct	Form 4 ↗0001022079-26-000085
2026-07-22Filed 2026-07-27	Gregg Vicky BDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	A Award / grantCommon Stock · Non-derivative	72A	206.808	Direct	Form 4 ↗0001022079-26-000084
2026-07-22Filed 2026-07-27	Plewman PatrickOfficer · SVP for Diagnostic Services Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	46A	206.807	Direct	Form 4 ↗0001022079-26-000083
2026-07-22Filed 2026-07-27	MAIN TIMOTHY LDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	21A	206.81	Direct	Form 4 ↗0001022079-26-000082
2026-07-22Filed 2026-07-27	SAMAD SAMOfficer · Executive Vice President & CFO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted share units. F2 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1, F2	A Award / grantCommon Stock · Non-derivative	102A	206.807	Direct	Form 4 ↗0001022079-26-000081
2026-07-22Filed 2026-07-27	Lassiter Wright IIIDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1	L Other reported codeCommon Stock · Non-derivative	6A	206.813	Direct	Form 4 ↗0001022079-26-000080
2026-07-22Filed 2026-07-27	DELANEY MARK EOfficer · SVP & Chief Commercial Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents an award of restricted share units. F2 Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. References: F1, F2	L Other reported codeCommon Stock · Non-derivative	34A	206.807	Direct	Form 4 ↗0001022079-26-000079
2026-07-01Filed 2026-07-02	WENTWORTH TIMOTHY CDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. References: F1	A Award / grantPhantom Stock Units · Derivative	144A	0	Direct	Form 4 ↗0001022079-26-000060
2026-06-04Filed 2026-06-08	KUPPUSAMY KARTHIKOfficer · SVP, Clinical Solutions Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F4 The options vested in three annual installments beginning with the first on February 24, 2023, the second on February 24, 2024 and the final on February 24, 2025. F5 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F1, F5	M Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative	4,827D	121.805	Direct	Form 4 ↗0001022079-26-000053
2026-06-04Filed 2026-06-08	KUPPUSAMY KARTHIKOfficer · SVP, Clinical Solutions Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F4 The options vested in three annual installments beginning with the first on February 24, 2023, the second on February 24, 2024 and the final on February 24, 2025. F5 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F1, F4	M Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative	3,320D	127.725	Direct	Form 4 ↗0001022079-26-000053
2026-06-04Filed 2026-06-08	KUPPUSAMY KARTHIKOfficer · SVP, Clinical Solutions Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2 The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. F3 These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. F4 The options vested in three annual installments beginning with the first on February 24, 2023, the second on February 24, 2024 and the final on February 24, 2025. F5 The options vested in three annual installments beginning with the first on February 17, 2022, the second on February 17, 2023 and the final on February 17, 2024. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	8,147D	200	Direct	Form 4 ↗0001022079-26-000053

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.